Francois Brisebois
Stock Analyst at Oppenheimer
(1.98)
# 3,155
Out of 4,989 analysts
88
Total ratings
38.64%
Success rate
-7.09%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics | Maintains: Outperform | $7 → $8 | $5.42 | +47.60% | 3 | Sep 8, 2025 | |
| SVRA Savara | Maintains: Outperform | $5 → $6 | $3.51 | +70.94% | 6 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $9.02 | +786.92% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $5.55 | +188.29% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $1.40 | +185.71% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $55.26 | +30.29% | 7 | Jan 22, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $26.76 | +127.95% | 6 | Jan 13, 2025 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $9.82 | +103.67% | 4 | Dec 17, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $5.15 | +444.22% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $15.59 | +92.43% | 8 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $143 → $163 | $48.97 | +232.86% | 4 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $13.17 | +317.62% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $19.14 | -21.61% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $6.85 | -12.41% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $3.08 | +257.14% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $23.97 | -41.59% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.34 | +476.04% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $14.84 | +338.01% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $5.01 | +99.60% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $6.04 | +2,416.56% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $18.02 | +99.78% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $60 | $0.21 | +28,430.67% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $1.76 | +306,718.18% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $3.09 | +255.99% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $4.38 | +310.96% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $5.54 | +802.53% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $1.44 | +224,900.00% | 1 | Feb 4, 2020 |
Aquestive Therapeutics
Sep 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $5.42
Upside: +47.60%
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $3.51
Upside: +70.94%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $9.02
Upside: +786.92%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $5.55
Upside: +188.29%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $1.40
Upside: +185.71%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $55.26
Upside: +30.29%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $26.76
Upside: +127.95%
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $9.82
Upside: +103.67%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $5.15
Upside: +444.22%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $15.59
Upside: +92.43%
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $48.97
Upside: +232.86%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $13.17
Upside: +317.62%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $19.14
Upside: -21.61%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $6.85
Upside: -12.41%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $3.08
Upside: +257.14%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $23.97
Upside: -41.59%
Jun 25, 2024
Initiates: Outperform
Price Target: $25
Current: $4.34
Upside: +476.04%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $14.84
Upside: +338.01%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $5.01
Upside: +99.60%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $6.04
Upside: +2,416.56%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $18.02
Upside: +99.78%
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $0.21
Upside: +28,430.67%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $1.76
Upside: +306,718.18%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $3.09
Upside: +255.99%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $4.38
Upside: +310.96%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $5.54
Upside: +802.53%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $1.44
Upside: +224,900.00%